F2A4

F2A4 (also known as TDM-811) is a synthetic 17-amino acid peptide designed to serve as a functional mimetic of basic fibroblast growth factor (bFGF or FGF2). Developed by Tissue Design Inc. and licensed for development by 3-D Matrix, F2A4 aims to overcome the clinical and manufacturing limitations of recombinant bFGF protein, such as high production costs and poor stability. The peptide acts as an agonist of the fibroblast growth factor receptor 1 (FGFR1), triggering downstream signaling pathways (such as the MAPK/ERK pathway) that promote the proliferation, migration, and differentiation of mesenchymal stem cells, osteoblasts, and vascular endothelial cells. F2A4 is primarily being investigated for regenerative medicine applications, including the treatment of periodontal disease, alveolar bone resorption, and bone defects. It is often formulated with self-assembling peptide scaffolds (like RADA16) to provide a sustained-release delivery system that facilitates localized tissue repair and regeneration.

Other names

basic fibroblast growth factor substitute peptidebFGF substitute peptideFGF2-mimetic peptideFGF-2-mimetic peptideFGF 2-mimetic peptideFGF-2 substitute peptideFGF2 substitute peptideFGF 2 substitute peptide